)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Promimic
Promimic (PRO) investor relations material
Promimic Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary20 Aug, 2026
Executive summary
Net sales for Q2 2026 reached 12.0 MSEK, up 6% year-over-year, with core business revenues growing 14% currency-adjusted.
FDA approval was obtained for a new nanostructured ceramic implant surface, enabling commercial scaling and new market opportunities.
Major customers in spine and dental segments reported strong growth, with Curiteva doubling production capacity and Alphatec Spine growing 17%.
Cost control measures maintained profitability despite currency headwinds.
Financial highlights
Q2 2026 net sales: 12.0 MSEK (11.3), operating income: -1.4 MSEK (-1.3), net result: -1.5 MSEK (-1.5).
H1 2026 net sales: 20.8 MSEK (20.0), operating income: -4.9 MSEK (-4.9), net result: -5.0 MSEK (-6.0).
Cash flow for Q2: -2.3 MSEK (-5.2), cash at period end: 19.8 MSEK (28.4).
EBITDA for Q2: -22 TSEK (69), solid equity ratio at 80% (81%).
Outlook and guidance
Focus remains on expanding in the US and new market segments, leveraging recent FDA approval.
Royalty calculation changes in the dental segment expected to positively impact growth from Q3 onward.
Strategic goal: >25% CAGR and >40% EBITDA margin long-term.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Promimic
- Q1 2026 saw positive cash flow, core growth, and key milestones, supporting a strong outlook.PRO
Q1 2026 - 2025 saw modest sales growth, reduced losses, and record new customer agreements.PROQ4 2025
- Record sales growth and new FDA approvals drive future expansion and strong outlook.PROQ3 2025
- Record new agreements, positive EBITDA, and updated growth targets despite market headwinds.PROQ2 2025
- Sales up 6% in Q3, with record product approvals and strong royalty growth.PROQ3 2024
- Record sales and robust growth, with new clinical approvals fueling future expansion.PROQ2 2024
- Q1 2025 saw sales growth, new strategic deals, and improved cash flow despite a net loss.PROQ1 2025
- Record sales and clinical milestones achieved, with robust growth outlook for 2025.PROQ4 2024
Next Promimic earnings date
Q3 202619 Nov, 2026
Promimic
Next Promimic earnings date
Q3 202619 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Promimic AB is a Sweden-based biomaterial company specializing in the development, manufacture, and sale of innovative biomaterials designed to enhance osseointegration, or bone healing. Their core technology revolves around a unique, nano-thin surface treatment, which is applied to various implant materials to improve bone integration. .Promimic's products find their applications primarily in the orthopedic and dental implant markets, aiming to improve patient outcomes through enhanced healing processes. The company's innovative approach to biomaterials positions it as a key player in the medical implant industry, providing solutions that cater to the increasing demand for advanced osseointegration technologies. The company is headquartered in Mölndal, Sweden, and its shares are listed on the Nasdaq First North Growth Market.